Paul Robert Hansen

Dr. Paul Robert Hansen

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
IGInes Greco
Ines Greco
NMNatalia Molchanova
Natalia Molchanova
EHElin Holmedal
Elin Holmedal
håvard jenssenhåvard jenssen
håvard jenssen
BHBernard D. Hummel
Bernard D. Hummel
JSJohan Svenson
Johan Svenson
The use of non-standard toxicity models is a hurdle in the early development of antimicrobial peptides towards clinical applications. Herein we report an extensive in vitro and in vivo toxicity study of a library of 24 peptide-based antimicrobials with narrow spectrum activity towards veterinary pathogens. The haemolytic activity of the compounds was evaluated against four different species and the relative sensitivity against the compounds was highest for canine erythrocytes, intermediate for rat and human cells and lowest for bovine cells. Selected peptides were additionally evaluated against HeLa, HaCaT and HepG2 cells which showed increased stability towards the peptides. Therapeutic indexes of 50–500 suggest significant cellular selectivity in comparison to bacterial cells. Three peptides were administered to rats in intravenous acute dose toxicity studies up to 2–8 × MIC. None of the injected compounds induced any systemic toxic effects in vivo at the concentrations employed illustrating that the correlation between the different assays is not obvious. This work sheds light on the in vitro and in vivo toxicity of this class of promising compounds and provides insights into the relationship between the different toxicity models often employed in different manners to evaluate the toxicity of novel bioactive compounds in general.

29 August 2017 in Molecules
Verified
Journal Article
Open access
PDF file
NMNatalia Molchanova
Natalia Molchanova
PHPaul Robert Hansen
Paul Robert Hansen
HFHenrik Franzyk
Henrik Franzyk
The rapid emergence of multidrug-resistant pathogens has evolved into a global health problem as current treatment options are failing for infections caused by pan-resistant bacteria. Hence, novel antibiotics are in high demand, and for this reason antimicrobial peptides (AMPs) have attracted considerable interest, since they often show broad-spectrum activity, fast killing and high cell selectivity. However, the therapeutic potential of natural AMPs is limited by their short plasma half-life. Antimicrobial peptidomimetics mimic the structure and biological activity of AMPs, but display extended stability in the presence of biological matrices. In the present review, focus is on the developments reported in the last decade with respect to their design, synthesis, antimicrobial activity, cytotoxic side effects as well as their potential applications as anti-infective agents. Specifically, only peptidomimetics with a modular structure of residues connected via amide linkages will be discussed. These comprise the classes of α-peptoids (N-alkylated glycine oligomers), β-peptoids (N-alkylated β-alanine oligomers), β3-peptides, α/β3-peptides, α-peptide/β-peptoid hybrids, α/γ N-acylated N-aminoethylpeptides (AApeptides), and oligoacyllysines (OAKs). Such peptidomimetics are of particular interest due to their potent antimicrobial activity, versatile design, and convenient optimization via assembly by standard solid-phase procedures.

1 June 2000 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
AOAnja Weinreich Olsen
Anja Weinreich Olsen
PHPaul Robert Hansen
Paul Robert Hansen
AHArne Holm
Arne Holm
PAPeter Andersen
Peter Andersen
We have investigated the vaccine potential of two peptides derived from the 6‐kDa early secretory antigenic target (ESAT)‐6 antigen in the mouse model of tuberculosis. The peptides were both strongly immunogenic in B6CBAF1 (H‐2b,k) mice and primed recall responses of the same intensity after immunization. However, both tuberculosis infection and immunization with ESAT‐6 resulted in responses focused towards ESAT‐61 – 20. Multiple antigen peptide constructs as well as free peptides were emulsified with dimethyl dioctadecylammonium bromide / monophosphoryl lipid A / IL‐2 and tested as experimental vaccines in an i. v. and aerosol model of tuberculosis in mice. The peptide were highly immunogenic and induced cellular responses of the same magnitude. However, only vaccines based on the subdominant ESAT‐651 – 70 epitope promoted significant levels of protective immunity and the level of protection was equivalent to that achieved with ESAT‐6 and BCG. These findings demonstrate the potential of peptide‐based vaccines against tuberculosis and indicate that there is not direct correlation between the hierarchy of response to naturally processed peptides and their ability to induce protective immunity against Mycobacterium tuberculosis.

25 December 2016
Verified
Book Chapter
Closed access
PDF file
AOAlberto Oddo
Alberto Oddo
PHPaul Robert Hansen
Paul Robert Hansen

Verified
Journal Article
Open access
PDF file
NTNicole Hartwig Trier
Nicole Hartwig Trier
PHPaul Robert Hansen
Paul Robert Hansen
GHGunnar Houen
Gunnar Houen
The applications of peptides and antibodies to multiple targets have emerged as powerful tools in research, diagnostics, vaccine development, and therapeutics. Antibodies are unique since they, in theory, can be directed to any desired target, which illustrates their versatile nature and broad spectrum of use as illustrated by numerous applications of peptide antibodies. In recent years, due to the inherent limitations such as size and physical properties of antibodies, it has been attempted to generate new molecular compounds with equally high specificity and affinity, albeit with relatively low success. Based on this, peptides, antibodies, and peptide antibodies have established their importance and remain crucial reagents in molecular biology.

9 September 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
NMNatalia Molchanova
Natalia Molchanova
JNJosefine Eilsø Nielsen
Josefine Eilsø Nielsen
KSKristian B. Sørensen
Kristian B. Sørensen
BPBala Krishna Prabhala
Bala Krishna Prabhala
PHPaul Robert Hansen
Paul Robert Hansen
håvard jenssenhåvard jenssen
håvard jenssen
Antimicrobial peptides have attracted considerable interest as potential new class of antibiotics against multi-drug resistant bacteria. However, their therapeutic potential is limited, in part due to susceptibility towards enzymatic degradation and low bioavailability. Peptoids (oligomers of N-substituted glycines) demonstrate proteolytic stability and better bioavailability than corresponding peptides while in many cases retaining antibacterial activity. In this study, we synthesized a library of 36 peptoids containing fluorine, chlorine, bromine and iodine atoms, which vary by length and level of halogen substitution in position 4 of the phenyl rings. As we observed a clear correlation between halogenation of an inactive model peptoid and its increased antimicrobial activity, we designed chlorinated and brominated analogues of a known peptoid and its shorter counterpart. Short brominated analogues displayed up to 32-fold increase of the activity against S. aureus and 16- to 64-fold against E. coli and P. aeruginosa alongside reduced cytotoxicity. The biological effect of halogens seems to be linked to the relative hydrophobicity and self-assembly properties of the compounds. By small angle X-ray scattering (SAXS) we have demontrated how the self-assembled structures are dependent on the size of the halogen, degree of substitution and length of the peptoid, and correlated these features to their activity.